SILO Silo Pharma Inc.

Subscribe to $SILO

Silo Pharma Inc.

Subscribe to $SILO

$SILO

Apparel

Consumer Discretionary

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for Silo Pharma Inc.

Date	Price Target	Rating	Analyst

See more ratings

Silo Pharma Inc. Press Releases

Fastest customizable press release news feed in the world

View All

Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that are immediately exer

10/1/25 4:20:00 PM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that wil

9/30/25 8:02:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management

Fireblocks is a globally recognized leader in the digital assets space, facilitating the secure transfer of more than $10 trillion to date SARASOTA, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, announced that it has begun implementing its strategic agreement with Fireblocks, an enterprise platform for secure digital asset custody, settlement, trading operations, and stablecoin payments, to provide institutional-grade infrastructure for its crypto treasury management platform\. Eric Weisblum, CEO of Silo, commented, "Fireblocks brings unmatched ex

9/29/25 2:30:00 PM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security

SARASOTA, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has engaged Fireblocks, an enterprise platform for building blockchain applications and managing digital asset operations, as custodian for its institutional crypto treasury platform. "Our engagement with Fireblocks is expected to ensure that our newly deployed crypto treasury platform is built with enterprise grade security and governance standards," said Silo CEO Eric Weisblum. "We believe that Fireblocks' proven institutional-grade infrastructure makes them the right pa

9/23/25 8:38:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Strategic capital deployment advances Company's blockchain treasury model and biopharma development initiatives SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchases of crypto tokens under its recently announced cryptocurrency treasury strategy targeting multi-chain asset growth. The Company's acquisition of Ethereum (ETH) and Solana (SOL) tokens marks the first step toward incorporating cryptocurrency into its treasury holdings and lays the foundation for Silo's broader blockchain and real world asset (RWA)

9/16/25 8:11:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug

SARASOTA, FL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that the Japan Patent Office has granted patent number 7683882 to Silo's research and licensing partner Columbia University for the invention titled "Prophylactic efficacy of serotonin 4 receptor agonists against stress," exclusively licensed to Silo by Columbia University. Columbia University recently received an Australian patent for the same invention. The patent reinforces protection for Silo's lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disord

9/9/25 9:10:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that IP Australia (the Australian Patent Office) has granted patent number 2020271839 to Silo's research and licensing partner Columbia University for the invention titled "Prophylactic efficacy of serotonin 4 receptor agonists against stress" exclusively licensed to Silo by Columbia University. The patent reinforces protection for Silo's lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD), originally developed by Columbia University. "Thi

9/3/25 8:25:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

SPC-15's intranasal spray formulation meets safety standards for clinical trial development SARASOTA, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced positive bioanalytical and safety/toxicology results for its U.S. Food and Drug Administration (FDA)-requested 7-day large animal safety study of its lead asset SPC-15. Silo CEO Eric Weisblum commented, "Overall, we believe the positive results of this study confirm that SPC-15's formulation and spray profile meets the safety standards for clinical trials. While the safety of the oral coun

8/19/25 8:05:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

8/5/25 8:32:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced completion of dosing in a U.S. Food and Drug Administration (FDA)-requested 7-day safety and toxicology large animal study of its lead asset SPC-15, and bioanalytical and safety/toxicology results for such study are expected within 60 days. "Our novel PTSD drug candidate SPC-15 has already shown strong safety and therapeutic delivery, and we are confident about the final data results from our preclinical discovery program," said Eric Weisblum, CEO of Silo. "We rem

7/16/25 8:45:00 AM ET

$SILO

Apparel

Consumer Discretionary

Silo Pharma Inc.

Recent Analyst Ratings for Silo Pharma Inc.

Silo Pharma Inc.

Recent Analyst Ratings for Silo Pharma Inc.

Silo Pharma Inc. Insider Purchases

Chief Executive Officer Weisblum Eric bought $4,329 worth of shares (10,000 units at $0.43), increasing direct ownership by 5% to 197,932 units (SEC Form 4)

CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

CEO and President Weisblum Eric bought $5,533 worth of shares (5,000 units at $1.11), increasing direct ownership by 3% to 180,432 units (SEC Form 4)

Weisblum Eric bought $1,988 worth of shares (1,000 units at $1.99), increasing direct ownership by 0.57% to 175,432 units (SEC Form 4)

Weisblum Eric bought $8,713 worth of shares (4,508 units at $1.93), increasing direct ownership by 3% to 174,432 units (SEC Form 4)

Weisblum Eric bought $1,137 worth of shares (700 units at $1.62), increasing direct ownership by 0.41% to 169,924 units (SEC Form 4)

Weisblum Eric bought $1,668 worth of shares (1,100 units at $1.52), increasing direct ownership by 0.65% to 169,224 units (SEC Form 4)

Weisblum Eric bought $1,376 worth of shares (1,000 units at $1.38), increasing direct ownership by 0.60% to 168,124 units (SEC Form 4)

Weisblum Eric bought $3,100 worth of shares (2,000 units at $1.55), increasing direct ownership by 1% to 167,124 units (SEC Form 4)

Silo Pharma Inc. SEC Filings

Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

SEC Form 424B5 filed by Silo Pharma Inc.

SEC Form DEFA14A filed by Silo Pharma Inc.

SEC Form DEF 14A filed by Silo Pharma Inc.

SEC Form PRE 14A filed by Silo Pharma Inc.

SEC Form 424B5 filed by Silo Pharma Inc.

SEC Form 10-Q filed by Silo Pharma Inc.

Silo Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Silo Pharma Inc. Insider Trading

Chief Executive Officer Weisblum Eric bought $4,329 worth of shares (10,000 units at $0.43), increasing direct ownership by 5% to 197,932 units (SEC Form 4)

SEC Form 4 filed by Director Linsley Wayne

SEC Form 4 filed by Director Munoz Kevin

SEC Form 4 filed by Chief Financial Officer Ryweck Daniel E.

SEC Form 4 filed by Chief Executive Officer Weisblum Eric

SEC Form 4 filed by Director Pavell Jeff

CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

CEO and President Weisblum Eric bought $5,533 worth of shares (5,000 units at $1.11), increasing direct ownership by 3% to 180,432 units (SEC Form 4)

Weisblum Eric bought $1,988 worth of shares (1,000 units at $1.99), increasing direct ownership by 0.57% to 175,432 units (SEC Form 4)

Silo Pharma Inc. Leadership Updates

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Silo Pharma Inc. Large Ownership Changes

SEC Form SC 13G filed by Silo Pharma Inc.

SEC Form SC 13G filed by Silo Pharma Inc.

SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

Silo Pharma Inc. Press Releases

Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management

Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15